Although previous studies have already demonstrated the effectiveness of several THRβ agonists in reducing hepatic steatosis in animal models (47–49), the effect of THRβ-selective thyromimetics on the regression of preneoplastic lesions remained largely unexplored. The gene discussed is THRB; the disease is fatty liver disease.